

Neuralstem, Inc.
Form 424B3
January 15, 2014

SUPPLEMENT No. 5

Rule 424(b)(3)

DATED JANUARY 15, 2014

Registration No. 333-165973

(To Prospectus dated May 11, 2010)

NEURALSTEM, INC.

5,163,956 Shares of Common Shares

This prospectus supplement (“Supplement”) modifies, supersedes and supplements information contained in, and should be read in conjunction with that certain prospectus, dated May 11, 2010, related to the resale of our common stock from time to time by certain shareholders (“Prospectus”), of Neuralstem, Inc. (“Company”), as well as all prior supplements thereto. This supplement is not complete without, and may not be delivered or used except in connection with, the Prospectus and all prior supplements thereto.

The information contained in this Supplement modifies and supersedes, in part, the information in the Prospectus, as supplemented. Any information that is modified or superseded in the Prospectus shall not be deemed to constitute a part of the Prospectus, except as modified or superseded by this Supplement.

We may amend or supplement the Prospectus from time to time by filing amendments or supplements as required. You should read the entire Prospectus and any amendments or supplements carefully before you make an investment decision.

Investing in our common stock involves a high degree of risk. You are urged to read the section entitled “Risk Factors” beginning on page 3 of the Prospectus, which describes specific risks and other information that should be considered before you make an investment decision.

FORWARD-LOOKING STATEMENTS

You should carefully consider the risk factors set forth in the prospectus, as well as the other information contained in this supplement and the prospectus. This supplement and the prospectus contain forward-looking statements regarding events, conditions, and financial trends that may affect our plan of operation, business strategy, operating results, and financial position. You are cautioned that any forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Actual results may differ materially from those included within the forward-looking statements as a result of various factors. Cautionary statements in the “Risk Factors” section of the prospectus identify important risks and uncertainties affecting our future, which could cause actual results to differ materially from the forward-looking statements made in this supplement and the prospectus.

SELLING SHAREHOLDERS

The Company has been notified by Apex Investment Fund, Inc. (“Apex”) that all the securities previously registered to it has been transferred. Accordingly, the Selling Shareholder table is being amended with regard to these transfers in order to update the new selling shareholder’s identity and to remove Apex as a selling shareholder. Unless amended, all other information contained in the selling shareholder table, as previously modified or amended, is unaffected:

	Common Shares Owned Before Sale				Shares being registered	Common Shares Owned After Sale	
	Held Outright	Warrants/Options	Amount	% of class		Amount	% of Class
Peter Schlesinger (1)	-	220,000	220,000	*	220,000	-	*

*Less than 1%

(1)The selling shareholder received the warrants pursuant to a warrant assignment.